NCT04436133已完成2 期
A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years
National Vaccine and Serum Institute, China1 个研究点 分布在 1 个国家目标入组 480 人开始时间: 2020年6月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 480
- 试验地点
- 1
- 主要终点
- Anti-HPV neutralizing antibody positive conversion rate（after full immunization 30 days）
研究概览
简要总结
A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or control vaccine according to the 0, 2, and 6 months immunization program.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 26 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Chinese women aged 18-26 who can provide legal identification;
- •The subject has the ability to understand the research procedure and sign an informed consent;
- •Subjects have the ability to read, understand, fill out diary cards/contact cards and other research application forms and promise to participate in regular follow-up as required by the research;
- •No previous history of HPV vaccination, no participation in HPV vaccine clinical trials, and no plans to receive HPV vaccine during the study period; The subject was not breastfeeding or pregnant (negative urine pregnancy test), did not have a birth plan within 7 months of enrollment; and from day 1 of the last menstrual cycle to day 0 of the study, did not have sex with men or with men Effective contraception was used during sex and no contraceptive failures occurred (examples of contraceptive failure include male condom rupture during sex). And agreed to continue to take effective contraceptive measures within the first 7 months after participating in the study (effective contraceptive measures include: oral contraceptives, hormone patches, intrauterine devices, condoms, cervical caps, etc.).
排除标准
- •Previous history of cervical lesions (such as abnormal cervical cancer screening, history of CIN disease) or history of hysterectomy surgery (vaginal or total hysterectomy) or history of pelvic radiation therapy; previous history of external genital diseases (such as vulvar epithelium) Neoplasia, intraepithelial neoplasia and genital warts, etc.);
- •Previous history of severe allergic reactions requiring medical intervention for any vaccine or drug (including yeast) (eg: anaphylactic shock, allergic throat edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction) Wait);
- •Immune function is impaired or has been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile Rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;
- •Long-term treatment with immunosuppressive agents, such as: long-term (more than 2 weeks in a row) treatment with glucocorticoids (eg, prednisone or similar drugs);
- •Receive any immunoglobulin or blood products within 3 months before vaccination, or plan to receive such products before the 7th month of the study;
- •Received inactivated vaccine or recombinant vaccine within 14 days before vaccination, or received any live vaccine within 28 days;
- •Loss of spleen or functional spleen, and removal of spleen or spleen caused by any situation;
- •Has been diagnosed with a disease that may interfere with the progress or completion of the study, such as: suffering from severe cardiovascular disease (pulmonary heart disease, pulmonary edema), severe liver and kidney disease, diabetes with complications, etc.; or has been diagnosed with Infectious diseases, such as: active tuberculosis, hepatitis B, hepatitis C, etc.;
- •A history of convulsions, epilepsy, encephalopathy, mental illness, family history of mental illness, etc.;
- •There are thrombocytopenia or other coagulation disorders that can be contraindications to intramuscular injection; 11.3 days before the vaccination, suffering from acute disease or in the acute onset of chronic disease or using antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, cetaxidine Tirizine, etc.);
- •12.Body temperature before inoculation≥37.3℃(armpit body temperature);
- •People who have a systolic blood pressure ≥140mmHg and/or a diastolic blood pressure ≥90mmHg before enrollment;
- •Participate or plan to participate in other clinical trials (drugs, vaccines and medical devices) during the study;
- •Plan to move out of the local area before the end of the study or leave the area for a long time during the scheduled study visit;
- •Exclusion criteria for second and third doses of vaccination:
- •Before vaccination (the day of vaccination), pregnant or urine pregnancy test (HCG) is positive; Note: If the subject chooses to terminate the pregnancy, at least 6 weeks after the end of pregnancy and the urine pregnancy test is negative on the day before the vaccination, or the medical certificate of termination of pregnancy issued after the end of pregnancy indicates that HCG levels have returned to normal levels, you can continue Vaccination; if you choose to continue pregnancy, you will not be vaccinated for subsequent doses.
- •Newly discovered or newly occurred conditions that meet the first dose exclusion criteria (except Articles 1 and 13);
- •Other serious adverse events: The researcher decides whether to terminate the test vaccination according to his treatment needs;
- •The investigator assessed any other reasons why the vaccination for the trial should be terminated.
结局指标
主要结局
Anti-HPV neutralizing antibody positive conversion rate（after full immunization 30 days）
时间窗: 30 days after full immunization
Collect all SAEs
时间窗: through study completion, an average of 13 months
Vaccine-related and unrelated
Collect AEs incidence
时间窗: Within 30 days after inoculation
All AEs: incidence of AEs related to vaccines and unrelated The rate of Solicited for AE Non-collective AEs: incidence of AEs related to vaccines and unrelated AE level 3 and above: incidence of vaccine-related and unrelated AEs
collect AEs leading subject to withdrawal
时间窗: through study completion, an average of 13months
Incidence of vaccine-related and unrelated AEs
collect All pregnancy conditions and pregnancy outcomes
时间窗: through study completion, an average of 13 months
collect pregnant woman Anti-HPV neutralizing antibody positive conversion rate and Anti-HPV neutralizing antibodies GMT
Anti-HPV neutralizing antibodies GMT
时间窗: 30 days after full immunization
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsHPV InfectionHPV-Related Cervical CarcinomaNCT04083196National Vaccine and Serum Institute, China90
Unknown
1 期
A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 YearsHPV Infection Vaccine Safety SCT1000NCT04921111Sinocelltech Ltd.240
进行中（未招募）
1 期
Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy SubjectsHealthyNCT05125211Zhejiang Echon Biopharm Limited91
已完成
1 期
A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416Secondary HyperparathyroidismNCT03283098Amgen33
已完成
4 期
Health Benefits of Functional Meat (With n-3 Fatty Acids and Rosemary Extract) on Low Risk for Cardiovascular Disease PeopleLow Risk for Cardiovascular DiseaseNCT01999088Instituto de Investigación Hospital Universitario La Paz44